{"id":57868,"date":"2021-05-17T13:03:36","date_gmt":"2021-05-17T11:03:36","guid":{"rendered":"http:\/\/www.veeva.com\/eu\/?post_type=resources&p=57868"},"modified":"2023-10-27T16:11:05","modified_gmt":"2023-10-27T14:11:05","slug":"oncopeptides-partners-with-veeva-to-drive-more-effective-engagement-ahead-of-first-commercial-launch","status":"publish","type":"resources","link":"https:\/\/www.veeva.com\/eu\/resources\/oncopeptides-partners-with-veeva-to-drive-more-effective-engagement-ahead-of-first-commercial-launch\/","title":{"rendered":"Oncopeptides Partners with ³Ô¹Ï±¬ÁÏ to Drive More Effective Engagement Ahead of First Commercial Launch"},"content":{"rendered":"

³Ô¹Ï±¬ÁÏ Link provides biotech with valuable market insights about top scientific and clinical leaders<\/em><\/p>\n

BARCELONA, Spain \u2014 17 May 2021 \u2014<\/strong> ³Ô¹Ï±¬ÁÏ Systems<\/a> (NYSE: VEEV) today announced a strategic partnership with Oncopeptides to support the launch of the global biotech\u2019s first commercial product. Using ³Ô¹Ï±¬ÁÏ Link<\/a> for real-time customer intelligence, Oncopeptides recently launched PEPAXTO\u00ae (melphalan flufenamide), the first anticancer peptide-drug conjugate approved by the U.S. Food and Drug Administration (FDA)<\/a> for multiple myeloma. <\/p>\n

\u201cEngaging the right healthcare providers (HCPs) is key in determining how fast we can reach patients battling difficult-to-treat hematological diseases,\u201d said Mohamed H. Ladha, general manager of the U.S. business unit at Oncopeptides. \u201c³Ô¹Ï±¬ÁÏ Link has given our medical and commercial teams the strategic insights they need to accelerate our launch and make meaningful connections from day one and beyond.\u201d<\/p>\n

Oncopeptides used ³Ô¹Ï±¬ÁÏ Link to quickly identify top scientific and clinical experts during pre-commercial planning, better engage with them, and uncover key market-level insights. ³Ô¹Ï±¬ÁÏ Link\u2019s in-depth oncology expert profiles inform more value-driven field interactions\u2014both in the critical early days of a launch and throughout ongoing commercialization activities. This supports the company\u2019s field force territory planning, key opinion leader (KOL) mapping, target account profiling, and speaker bureau selection. <\/p>\n

The biotech also benefits from ³Ô¹Ï±¬ÁÏ\u2019s full suite of Commercial Cloud<\/a> applications, including solutions for multichannel engagement<\/a>, commercial content<\/a>, and customer data<\/a>. These capabilities deliver data-driven insights and facilitate smarter, compliant HCP interactions across all channels.<\/p>\n

\u201cWe\u2019re proud to partner with Oncopeptides to help bring this important therapy to the market,\u201d said Kilian Weiss, general manager for ³Ô¹Ï±¬ÁÏ Link at ³Ô¹Ï±¬ÁÏ Systems. \u201cThe company\u2019s dynamic field force is taking a digital-first approach to customer engagement\u2014helping accelerate commercial success and support long-term, agile relationships\u2014even as HCP preferences and access continue to evolve.\u201d<\/p>\n

Used by five of the ten largest pharmaceutical companies, ³Ô¹Ï±¬ÁÏ Link speeds market readiness for new life sciences products. It provides fully compliant, real-time profiles on tens of thousands of scientific experts and millions of activities in a single enterprise view. With this strategic visibility, sales, marketing, and medical teams gain deeper market insights, grow relationships, and add value to customer interactions. <\/p>\n

For more information on how Oncopeptides used these market-level insights to accelerate its launch, register for the upcoming ³Ô¹Ï±¬ÁÏ Commercial & Medical North America Summit Connect<\/a> on June 10, 2021. The live one-day virtual event is open to life sciences industry professionals. <\/p>\n

Additional Information<\/strong>
\nFor more on ³Ô¹Ï±¬ÁÏ Link, visit: veeva.com\/eu\/veeva-link<\/a>
\nConnect with ³Ô¹Ï±¬ÁÏ on LinkedIn: linkedin.com\/company\/veeva-systems<\/a>
\nFollow @veeva_eu on Twitter: twitter.com\/veeva_eu<\/a><\/p>\n

About Oncopeptides<\/strong>
\nOncopeptides is a global biotech company committed to developing targeted therapies for patients facing hard-to-treat hematological diseases. Oncopeptides has one U.S. FDA approved product, PEPAXTO\u00ae (melphalan flufenamide), known during clinical development as melflufen. PEPAXTO is approved for some patients with triple-class refractory multiple myeloma and was evaluated in several clinical studies including the pivotal Phase 2 HORIZON study and is currently being evaluated in the confirmatory Phase 3 OCEAN study. Oncopeptides\u2019 headquarters is in Stockholm, Sweden, with a U.S. headquarters in Boston, Massachusetts. In addition to Boston, Oncopeptides has a footprint in San Francisco, California, another U.S. biotech hub. For more information, please visit our corporate website at https:\/\/oncopeptides.se\/en\/<\/a>. You may also visit our U.S. website at https:\/\/www.oncopeptides-us.com\/en<\/a> and follow us on our U.S. social media channels, Twitter<\/a> and LinkedIn<\/a>. PEPAXTO\u00ae is a trademark of Oncopeptides AB (publ).<\/p>\n

About ³Ô¹Ï±¬ÁÏ Systems<\/strong>
\n³Ô¹Ï±¬ÁÏ is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 975 customers, ranging from the world\u2019s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, ³Ô¹Ï±¬ÁÏ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com\/eu<\/a>.<\/p>\n

Forward-looking Statements<\/strong>
\nThis release contains forward-looking statements, including the market demand for and acceptance of ³Ô¹Ï±¬ÁÏ\u2019s products and services, the results from use of ³Ô¹Ï±¬ÁÏ\u2019s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon ³Ô¹Ï±¬ÁÏ\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ³Ô¹Ï±¬ÁÏ\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ³Ô¹Ï±¬ÁÏ disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect ³Ô¹Ï±¬ÁÏ\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-K for the period ended January 31, 2021. This is available on the company\u2019s website at veeva.com<\/a> under the Investors section and on the SEC\u2019s website at sec.gov<\/a>. Further information on potential risks that could affect actual results will be included in other filings ³Ô¹Ï±¬ÁÏ makes with the SEC from time to time. <\/p>\n

###<\/p>\n

Contact:<\/strong><\/p>\n

Meagan Busath
\n³Ô¹Ï±¬ÁÏ Systems
\n925-452-6500
\nmeagan.busath@veeva.com<\/a><\/p>\n

Deivis Mercado
\n³Ô¹Ï±¬ÁÏ Systems
\n925-226-8821
\ndeivis.mercado@veeva.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

³Ô¹Ï±¬ÁÏ Link provides biotech with valuable market insights about top scientific and clinical leaders.<\/p>\n","protected":false},"featured_media":58115,"parent":0,"template":"","class_list":["post-57868","resources","type-resources","status-publish","has-post-thumbnail","hentry","search-do-not-search","resource-do-not-display-do-not-display","resource-social-hide-social-icons","resource-area-20-commercial","resource-product-20-commercial-data-warehouse-nitro","resource-type-news-press-release","resource-type-press-release"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/57868"}],"collection":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources"}],"about":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/types\/resources"}],"version-history":[{"count":1,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/57868\/revisions"}],"predecessor-version":[{"id":57876,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/57868\/revisions\/57876"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media\/58115"}],"wp:attachment":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media?parent=57868"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}